NCT06056804View on ClinicalTrials.gov

Neoadjuvant Chemoradiotherapy Combined With PD-1 Inhibitor and Thymalfasin for pMMR/MSS Locally Advanced Mid-low Rectal Cancer

PHASE2Active, not recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

January 3, 2024

Primary Completion Date

December 1, 2024

Study Completion Date

July 1, 2027

Conditions

Locally Advanced Rectal Cancer

Interventions

DRUG

capecitabine

825-1000mg/m2,po,bid

DRUG

tislelizumab

200mg,iv.gtt,q3w

DRUG

thymalfasin

4.8mg,sc,biw

RADIATION

long-term radiotherapy

50 Gy/25 f, 2 Gy/day

Trial Locations (2)

Unknown

Beijing Friendship Hospital,Capital Medical University, Beijing

Peking Union Medical College Hospital, Beijing

All Listed Sponsors

collaborator

Peking Union Medical College Hospital

OTHER

lead

Beijing Friendship Hospital

OTHER

NCT06056804 - Neoadjuvant Chemoradiotherapy Combined With PD-1 Inhibitor and Thymalfasin for pMMR/MSS Locally Advanced Mid-low Rectal Cancer | Biotech Hunter | Biotech Hunter